Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05QGH
|
||||
| Former ID |
DIB006127
|
||||
| Drug Name |
DXL-625
|
||||
| Synonyms |
DXLr-120; Anti-CD20 monoclonal antibodies (DXL, cancer), InNexus; Autophilic peptide conjuagted rituximab (rheumatoid arthritis/NHL/CLL), InNexus; Anti-CD20 monoclonal antibodies (DXL, non-Hodgkin's lymphoma/ rheumatoid arthritis), InNexus
|
||||
| Indication | Chronic lymphocytic leukaemia [ICD10:C91] | Investigative | [543668] | ||
| Company |
InNexus Biotechnology Inc
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Modulator | [543668] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.